Results

Total Results: 1,540 records

Showing results for "month".

81. Alcohol-Misuse Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/alcohol-misuse_executive.pdf
    April 28, 2010 - distress, as manifested by three (or more) of the following, occurring at any time in the same 12-month … Data are reported for 12-month outcomes unless otherwise noted. Table G. … Data are reported for 12-month outcomes unless otherwise noted. 12 difference [WMD], -5.0 drinks … Data are reported for 12-month outcomes unless otherwise noted. 13 Discussion We aimed to conduct … Results at 12-month follow-up. J Gen Intern Med. 2005 Jan; 20(1):7-13. PMID: 15693921. 68.

82. Arthritis and Nontraumatic Joint Disease (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1306.pdf
    June 01, 2013 - reoperation rates, complications, and recovery times compared with those outcomes with ACDF at 24-month … rate for patients treated with Mobi-C was reported as 70.59% compared with 36.36% for ACDF at 24-month … (n=12) and 12-month (n=10) followup. … better than at baseline (p<0.0005).70 By 24-month followup, all evaluated outcomes were significantly … lower than those observed at 12-month followup.

83. Version-3-Immunity-After-Covid-19-Appendix-Table-B-1 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/version-3-immunity-after-COVID-19-appendix-table-B-1.xlsx
    January 24, 2022 - 29 (21.5) >=two: 25 (18.5) Chemiluminescent immunoassay Roche Elecsys anti-SARS-CoV-2 immunoassay 1 month … It reports 12 month ab data ~No symptomatic reinfections were observed in any of the study groups during … transplant patients PMID: 33756051 https://pubmed.ncbi.nlm.nih.gov/33756051/ Spain Prospective cohort ~ 1 month … Test CMIA; Anti-N-IgG Architect chemiluminescent micropartical immunoassay CMIA Abbott Laboratories 1 month … 3 months 6 months 9 months Up to 9 months with sampling planned every third month All participants

84. Arthritis and Nontraumatic Joint Disease (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1406.pdf
    June 01, 2014 - (n=12) and 12-month (n=10) followup. … and Numeric Rating Scale scores were observed in patients who received PRP injections at 3- and 6-month … , 2, or 3 were treated with three weekly injections of PRP or hyaluronic acid and evaluated at 12-month … better than at baseline (p<0.0005).38 By 24-month followup, all evaluated outcomes were significantly … lower than those observed at 12-month followup.

85. Evidence-Summary-CER-209-Noninvasive-Nonpharmacological-Treatment-For-Chronic-Pain (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-209-evidence-summary-non-pharma-chronic-pain.pdf
    June 01, 2018 - Key Messages • Interventions that improved function and/ or pain for at least 1 month when used for— … Therefore, this report focuses on durability of treatment effects, defined as at least 1 month following … We assessed the persistence of effects for therapies at least 1 month following completion of a course … We focused on randomized controlled trials (RCTs) reporting outcomes at least 1 month following the … We focused on evaluating the sustainability of effects for at least 1 month post- intervention.

86. Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review Update - Evidence Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/noninvasive-nonpharm-pain-summary.pdf
    April 01, 2020 - Key Messages • Interventions that improved function and/or pain for ≥1 month: – Low back pain: Exercise … Therefore, this report focuses on durability of treatment effects, defined as at least 1 month following … We assessed the persistence of effects for therapies at least 1 month following completion of a course … We focused on randomized controlled trials (RCTs) reporting outcomes at least 1 month following the … We focused on evaluating the sustainability of effects for at least 1 month postintervention.

87. Outcomes in COPD patients treated with theophylline (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/decide16final-mortality-risk-in-copd-pts-using-theophylline.pdf
    December 01, 2009 - The first assigned patients to groups based on combinations of medication received during the six month … Respiratory medication regimens were defined for each six month increment during follow-up. … Patients were defined as exposed if they had a dispensing for that medication during the six month … patients exposed to theophylline, similar to results when exposure was defined based on a fixed six month … 0.3 0.7 0.5 1.0 1.0 1.2 3+ 0.1 0.4 0.3 0.5 0.5 0.7 aNo COPD related visits in previous 24-month

88. Outcomes in COPD patients treated with theophylline (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/copd-management_research.pdf
    December 01, 2009 - The first assigned patients to groups based on combinations of medication received during the six month … Respiratory medication regimens were defined for each six month increment during follow-up. … Patients were defined as exposed if they had a dispensing for that medication during the six month … patients exposed to theophylline, similar to results when exposure was defined based on a fixed six month … 0.3 0.7 0.5 1.0 1.0 1.2 3+ 0.1 0.4 0.3 0.5 0.5 0.7 aNo COPD related visits in previous 24-month

89. Intergrated and Comprehensive Pain Management Programs: Effectiveness and Harms: Evidence Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/cer-251-integrated-pain-management-evidence-summary.pdf
    October 01, 2021 - Intergrated and Comprehensive Pain Management Programs: Effectiveness and Harms: Evidence Summary Comparative Effectiveness Review Number 251 Integrated and Comprehensive Pain Management Programs: Effectiveness and Harms Evidence Summary Main Points Background and Purpose Pain affects millions …

90. Cancer-Drugs-Utilization Research (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/cancer-drugs-utilization_research.pdf
    January 01, 2011 - Proportions of beneficiaries with a cancer ICD-9 code within 1-, 3-, and 12-month periods of continuous … Gender, and Race, 2006-2009 Proportion of FFS Drug Users With a 200.x-208.x Cancer Diagnosis in 6-Month … All results presented used a 6-month lookback period from the first biologic order of interest. … Results using alternate lookback periods (1-, 3- and 12-month) are available online.

91. Treatments for Fecal Incontinence: Current State of the Evidence (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/fecal-incontinence_clinician.pdf
    July 01, 2016 - significantly decreased FI by 2.5 episodes per week versus placebo (0.7 fewer episodes per week) after 1 month … placebo 1 44 Severity No significant difference was found between groups in FICA score improvement at 1 month

92. S77 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/s77.pdf
    October 01, 2007 - In contrast to the VA, Part D plans charge only 1 copayment for medications dispensed with a 3-month … prescriptions filled for 30-day periods, we are unable to calculate the actual use of generic drugs or 3-month … conser- vative estimate, assuming all brand name usage and no prescription fills for longer than a month

93. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/prostate-cancer_executive.pdf
    February 01, 2008 - The trial comparing 3 months and 8 months neoadjuvant ADT with RP reported greater AEs in the 8-month … group than the 3- month group (4.5 percent vs. 2.9 percent) and higher incidence of hot flashes (87 … • Adverse effects and toxicity: There was no difference between 8- month and 3-month ADT in the type … and severity of AEs. 8-month ADT resulted in more AEs than 3-month ADT. … group than the 8-month group among low-risk subjects (N=92, PSA <10 ng/ml, stage T1c to T2a tumors,

94. Heart-Failure-Transition-Care Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/heart-failure-transition-care_executive.pdf
    May 01, 2014 - not readmitted at 30 days and 3 months, we considered the consistency of similar programs reducing 3-month … not be beneficial in long-term disease management in patients with HF (e.g., perhaps for reducing 12-month … then future studies should evaluate whether interventions that show efficacy in reducing 3- and 6-month

95. Gibbons (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/gibbons.pdf
    January 01, 2010 - Disparities” Percentage of respondents who visit social networking sites at least -­‐23  times per month

96. App-D-Opioid-Chronic-Pain-Surveillance-Report-3 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveillance-report-3.xlsx
    September 30, 2015 - Self-reported use of opiates: 89% Screened: 65 Eligible: 25 Randomized: 19 Analyzed: 19 LTFU: 9 Outcomes at 6 month … Duration: 12 month followup Inclusion: Patients with chronic opioid therapy (≥84 consecutive days of

97. Lumbar-Fusion-Draft-Report-Appendix-E (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/lumbar-fusion-draft-report-appendix-e.xlsx
    January 01, 2023 - Title Appendix E. Risk of Bias Assessments Table E-1. RCTs - Risk of Bias Table E-1. Risk of bias assessments for randomized controlled trials (RCTs) evaluating fusion procedures for degenerative spondylolisthesis (Key Questions [KQs] 1-4) and nonsurgical/select interventions for chronic low…

98. Disclosure Policy and Form (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/epc-disclosure-policy-form.pdf
    March 01, 2023 - Time period for financial interests disclosure: The instructions recommend a two year time window: 12 month … If planned or pending patent indicate in the 12 month look ahead anticipated value of future royalties … Time period for financial interests disclosure:  The instructions recommend a two year time window: 12 month … Time period for financial interests disclosure: The instructions recommend a two year time window: 12 month … If planned or pending patent indicate in the 12 month look ahead anticipated value of future royalties

99. CER 45 Self-Measured Blood Pressure Monitoring Comparative Effectiveness Surveillance Final 4.7.16 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/measuring-blood-pressure-surveillance-160412.pdf
    May 29, 2025 - The"original"systematic"review"did"not"draw"conclusions"for"three"month"or"nine"month" timeframes." … $The$meta" analyses$for$6"and$12"month$BP$outcome$included$five$and$six$ studies,$respectively,$with … outcome$was$the$difference$in$systolic$blood$pressure$between$intervention$and$control$ groups$at$the$12"month … $The$meta"analyses$ for$6"and$12"month$BP$ outcome$included$five$and$six$ studies,$respectively,$with … The$last$study$was$a$ randomized$trial 14 $of$213$ patients$which$assessed$ adherence$to$a$6"month

100. EPC Methods: An Exploration of Methods and Context for the Production of Rapid Reviews (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/rapid-review-production_white-paper.pdf
     February 01, 2015 - Policy maker Coverage F1 Rapid response 4 weeks N N Y N Policy maker Purchase U1 Rapid response 1 month … review 3 days Yes N/A No No Yes No E2 Rapid review 4 weeks Yes Yes No No Yes No H1 Rapid review 1 month … explicit review conclusion F1 Rapid response 4 weeks Yes Sometimes No No Yes U1 Rapid response 1 month … Rapid review 3 days Yes Yes Yes No Yes E2 Rapid review 4 weeks Yes Yes Yes No Yes H1 Rapid review 1 month … Evidence Briefing 1 month Narrative summary of existing evidence.